SlideShare ist ein Scribd-Unternehmen logo
1 von 24
Downloaden Sie, um offline zu lesen
PRESENTER : Dr.S.Waseemsha
2yr PG., Dept of PSM
GUIDE :Dr.(Col)M.V.Malhotra M.D.,(PSM)
Asst.Prof. Dept of PSM
OUTLINE OF THE PRESENTATION
• Introduction
• Burden
• Progress
• Challenges
• Developmental milestones of the strategy
• Vision and goal of the strategy
• Pillars and principles
• Reaching the targets
TUBERCULOSIS
• TB is a top killer worldwide due to a single
infectious agent.
• TB places its heaviest burden on the world’s
most poor and vulnerable, aggravating
existing in equalities.
• Due to TB , people face costs or suffer income
loss equivalent on average to more than 50%
of their income.
BURDEN
9 million people fell ill
with TB in 2013
1.5 million men, women and
children died from TB in 2013
1.1 million people living with HIV developed
TB, with 360,000 associated deaths in 2013
480 000 people developed MDR-TB (multidrug-
resistant TB) in 2013, with 210,000
associated deaths
PROGRESS
37 million lives saved between 2000 and 2013
through effective TB diagnosis and treatment
45% decline in TB mortality rate and 41%
decline in TB prevalence rate since 1990
HIV-related TB deaths down by 34% in the
last decade
Fragile progress in MDR-TB with the number of
people diagnosed tripling and a three-fold
increase in treatment coverage since 2009
CHALLENGES
US$ 2 billion funding gap per year for
implementation of existing TB interventions. There is
an additional gap of US$ 1.39 billion for research.
3 million people with TB are missed by health systems
every year and therefore may not get adequate care
they need
TB/HIV response needs acceleration . Antiretroviral
treatment, treatment of latent TB infection and other
key interventions still need further scale-up
MDR-TB remains a crisis Widening gaps between
people diagnosed with MDR-TB and those put on
treatment. This could compromise recent gains
World Health Assembly 2012
Call from Member States
At the 65th World Health Assembly in May 2012, Member States called upon WHO to
develop a new post-2015 TB strategy and targets, and present this to Member States at
the 67th World Health Assembly in 2014.
THE END TB STRATEGY
* The United Nations is in the process of defining a post-2015 development agenda. A set of “Sustainable
Development Goals” (SDGs) are being developed for 2030; TB is proposed to be part of the agenda and
goals.
The Strategy:
• Provides a unified response to ending TB deaths,
disease, and suffering.
• Builds on three strategic pillars underpinned by four
key principles.
PILLARS AND PRINCIPLES
PRINCIPLES
1. Government stewardship and accountability, with
monitoring and evaluation
2. Strong coalition with civil society organizations and
communities
3. Protection and promotion of human rights, ethics
and equity
4. Adaptation of the strategy and targets at country
level, with global collaboration
Pillar 1
INTEGRATED, PATIENT-
CENTRED CARE AND
PREVENTION
A. Early diagnosis of tuberculosis including universal drug-susceptibility
testing, and systematic screening of contacts and high-risk groups .
B. Treatment of all people with tuberculosis including drug-resistant
tuberculosis, and patient support .
C. Collaborative tuberculosis/HIV activities, and management of co-
morbidities
D. Preventive treatment of persons at high risk, and vaccination against
tuberculosis
Pillar 2
A. Political commitment with adequate resources for tuberculosis
care and prevention.
B. Engagement of communities, civil society organizations, and
public and private care providers.
C. Universal health coverage policy, and regulatory frameworks for
case notification, vital registration, quality and rational use of
medicines, and infection control.
D. Social protection, poverty alleviation and actions on other
determinants of tuberculosis .
BOLD POLICIES AND
SUPPORTIVE SYSTEMS
Pillar 3
INTENSIFIED RESEARCH AND
INNOVATION
A. Discovery, development and rapid uptake of new tools,
interventions and strategies
B. Research to optimize implementation and impact, and promote
innovations
The Global Strategy and targets for
Tuberculosis Prevention, Care and Control
after 2015, were endorsed by all member
states at the 2014 world health assembly.
REACHING THE TARGETS
Getting to the 2025 targets
requires effective use of
existing tools to combat TB,
complemented by universal
health coverage and social
protection to:
• Push down global TB incidence
rates from an annual decline
of 2% in 2015 to 10% by 2025.
• Reduce the proportion of
people with TB who die from
the disease from 15% in 2015
to 6.5% by 2025.
Moving forward to the 2035
targets requires the ensured
availability of new tools from
the research pipeline, in
particular:
• Better diagnostics, including
new point-of care tests;
• Safer, easier and shorter
treatment regimens;
• Safer and more effective
treatment for latent TB
infection;
• Effective pre- and post-
exposure vaccines.
Desired decline in global TB incidence rates to reach
the 2035 targets
MEASURING PROGRESS
• To assess and facilitate progress towards the
targets , WHO recommends that countries use
the following priority operational indicators.
• In 2015,WHO will issue an operational guide
with a comprehensive list of recommended
indicators and tools for adaptation and
implementation of the Strategy.
Treatment coverage
• Number of people that developed TB,
and were notified and treated, out of
the total estimated number of incident
cases in the same year (%).
TB treatment success rate
• Number of TB patients who were
successfully treated out of all notified
TB cases (%).
Preventive treatment coverage
• Number of people living with HIV and
children who are contacts of cases
who were started on preventive
treatment for latent TB infection, out
of all those eligible (%).
TB affected households facing
catastrophic costs
• Number of TB patients and their
households that experienced
catastrophic costs due to TB, out of all
TB patients (%)
Uptake of new diagnostics and new
drugs
• Number of TB patients who were
diagnosed using WHO-
recommended rapid tests, out of
all TB patients (%).
• Number of TB patients who were
treated with regimens including
new TB drugs, out of those
eligible for treatment with such
drugs (%).
END TB 2015 strategy

Weitere ähnliche Inhalte

Was ist angesagt?

Natural history of disease
Natural history of diseaseNatural history of disease
Natural history of diseasedrjagannath
 
Interpersonal Health Communication Interpersonal Media for Individual Health ...
Interpersonal Health Communication Interpersonal Media for Individual Health ...Interpersonal Health Communication Interpersonal Media for Individual Health ...
Interpersonal Health Communication Interpersonal Media for Individual Health ...Mohammad Aslam Shaiekh
 
Basic Concepts of PH
Basic Concepts of PHBasic Concepts of PH
Basic Concepts of PHamitakashyap1
 
Epidemiology of AIDS
Epidemiology of AIDSEpidemiology of AIDS
Epidemiology of AIDSAnusha Divvi
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISHarivansh Chopra
 
Infectious Disease Epidemiology
Infectious Disease EpidemiologyInfectious Disease Epidemiology
Infectious Disease EpidemiologyArvind Kushwaha
 
Association and causation
Association and causationAssociation and causation
Association and causationdrravimr
 
NCD Prevention and Control as a Health System Strengthening Intervention
NCD Prevention and Control as a Health System Strengthening InterventionNCD Prevention and Control as a Health System Strengthening Intervention
NCD Prevention and Control as a Health System Strengthening InterventionAlbert Domingo
 
End tb strategy
End tb strategyEnd tb strategy
End tb strategyrmch15cm
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TBRama shankar
 
levels of Prevention &modes of intervention
levels of Prevention &modes of interventionlevels of Prevention &modes of intervention
levels of Prevention &modes of interventionSwati Sirwar
 
NATURAL HISTORY OF DISEASE
NATURAL HISTORY OF DISEASENATURAL HISTORY OF DISEASE
NATURAL HISTORY OF DISEASESoumya Sahoo
 
National TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glanceNational TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glancePROFDRSUSMITAKUNDU
 
Planning for malaria elimination
Planning for malaria eliminationPlanning for malaria elimination
Planning for malaria eliminationNajibullah Safi
 
Introduction to Community Medicine Lecture
Introduction to Community Medicine LectureIntroduction to Community Medicine Lecture
Introduction to Community Medicine LectureDr.Farhana Yasmin
 

Was ist angesagt? (20)

Natural history of disease
Natural history of diseaseNatural history of disease
Natural history of disease
 
Interpersonal Health Communication Interpersonal Media for Individual Health ...
Interpersonal Health Communication Interpersonal Media for Individual Health ...Interpersonal Health Communication Interpersonal Media for Individual Health ...
Interpersonal Health Communication Interpersonal Media for Individual Health ...
 
Basic Concepts of PH
Basic Concepts of PHBasic Concepts of PH
Basic Concepts of PH
 
Epidemiology of AIDS
Epidemiology of AIDSEpidemiology of AIDS
Epidemiology of AIDS
 
NACP Basics
NACP BasicsNACP Basics
NACP Basics
 
End tb strategy
End tb strategyEnd tb strategy
End tb strategy
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSIS
 
Infectious Disease Epidemiology
Infectious Disease EpidemiologyInfectious Disease Epidemiology
Infectious Disease Epidemiology
 
Association and causation
Association and causationAssociation and causation
Association and causation
 
END TB 2025
END TB 2025END TB 2025
END TB 2025
 
NCD Prevention and Control as a Health System Strengthening Intervention
NCD Prevention and Control as a Health System Strengthening InterventionNCD Prevention and Control as a Health System Strengthening Intervention
NCD Prevention and Control as a Health System Strengthening Intervention
 
End tb strategy
End tb strategyEnd tb strategy
End tb strategy
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSIS
 
Infection control measures in tuberculosis Dr.T.V.Rao MD
Infection control measures in  tuberculosis Dr.T.V.Rao MDInfection control measures in  tuberculosis Dr.T.V.Rao MD
Infection control measures in tuberculosis Dr.T.V.Rao MD
 
Global and Indian plan to End TB
Global and Indian plan to End TBGlobal and Indian plan to End TB
Global and Indian plan to End TB
 
levels of Prevention &modes of intervention
levels of Prevention &modes of interventionlevels of Prevention &modes of intervention
levels of Prevention &modes of intervention
 
NATURAL HISTORY OF DISEASE
NATURAL HISTORY OF DISEASENATURAL HISTORY OF DISEASE
NATURAL HISTORY OF DISEASE
 
National TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glanceNational TB Elimination programme(NTEP) at a glance
National TB Elimination programme(NTEP) at a glance
 
Planning for malaria elimination
Planning for malaria eliminationPlanning for malaria elimination
Planning for malaria elimination
 
Introduction to Community Medicine Lecture
Introduction to Community Medicine LectureIntroduction to Community Medicine Lecture
Introduction to Community Medicine Lecture
 

Andere mochten auch

PPT Cirillo "I Stage: from Koch to Xpert"
PPT Cirillo "I Stage: from Koch to Xpert"PPT Cirillo "I Stage: from Koch to Xpert"
PPT Cirillo "I Stage: from Koch to Xpert"StopTb Italia
 
PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"StopTb Italia
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISANGAN KARMAKAR
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis pptUma Binoy
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentationRRR784
 
Heart failure
Heart failureHeart failure
Heart failureUNEP
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failureFuad Farooq
 

Andere mochten auch (10)

Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
 
PPT Cirillo "I Stage: from Koch to Xpert"
PPT Cirillo "I Stage: from Koch to Xpert"PPT Cirillo "I Stage: from Koch to Xpert"
PPT Cirillo "I Stage: from Koch to Xpert"
 
PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
Heart Failure
Heart FailureHeart Failure
Heart Failure
 
Pulmonary tuberculosis..ptt
Pulmonary tuberculosis..pttPulmonary tuberculosis..ptt
Pulmonary tuberculosis..ptt
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentation
 
Heart failure
Heart failureHeart failure
Heart failure
 
Heart failure / cardiac failure
Heart failure / cardiac failureHeart failure / cardiac failure
Heart failure / cardiac failure
 

Ähnlich wie END TB 2015 strategy

tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdfanchalyadav895389
 
Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal Public Health
 
2 Background on Tuberculosis.pptx
2  Background on Tuberculosis.pptx2  Background on Tuberculosis.pptx
2 Background on Tuberculosis.pptxRemedanSss
 
Towards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriTowards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriWAidid
 
Yes!? We can end TB - World Tuberculosis Day 2024.
Yes!? We can end TB - World Tuberculosis Day 2024.Yes!? We can end TB - World Tuberculosis Day 2024.
Yes!? We can end TB - World Tuberculosis Day 2024.Christina Parmionova
 
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptx
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptxWORLD TUBERCULOSIS DAY MARCH 24 2021.pptx
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptxanjalatchi
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxSanaKhader1
 
TB control programs in nepal
TB control programs in nepalTB control programs in nepal
TB control programs in nepalSurakshya Poudel
 
Viral hepatitis Elimination challenges and progress Final.pptx
Viral hepatitis Elimination challenges and progress Final.pptxViral hepatitis Elimination challenges and progress Final.pptx
Viral hepatitis Elimination challenges and progress Final.pptxDrHarsh Saxena
 
Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaKavya .
 
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxWORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxanjalatchi
 
Systematic home screening for active pulmonary tuberculosis in the San commun...
Systematic home screening for active pulmonary tuberculosis in the San commun...Systematic home screening for active pulmonary tuberculosis in the San commun...
Systematic home screening for active pulmonary tuberculosis in the San commun...Dalton Malambo
 
Systematic home screening for active pulmonary tuberculosis in the san commun...
Systematic home screening for active pulmonary tuberculosis in the san commun...Systematic home screening for active pulmonary tuberculosis in the san commun...
Systematic home screening for active pulmonary tuberculosis in the san commun...Dalton Malambo
 

Ähnlich wie END TB 2015 strategy (20)

tb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdftb-2102161hdidmkdijddbndksos85906 (2).pdf
tb-2102161hdidmkdijddbndksos85906 (2).pdf
 
Dots
DotsDots
Dots
 
Tuberculosis National Health Program in Nepal
Tuberculosis National Health Program  in Nepal Tuberculosis National Health Program  in Nepal
Tuberculosis National Health Program in Nepal
 
2 Background on Tuberculosis.pptx
2  Background on Tuberculosis.pptx2  Background on Tuberculosis.pptx
2 Background on Tuberculosis.pptx
 
End tb
End tbEnd tb
End tb
 
WORLD TB Day 2015
WORLD TB Day  2015 WORLD TB Day  2015
WORLD TB Day 2015
 
RNTCP.pptx
RNTCP.pptxRNTCP.pptx
RNTCP.pptx
 
Towards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista MiglioriTowards TB elimination - Giovanni Battista Migliori
Towards TB elimination - Giovanni Battista Migliori
 
Yes!? We can end TB - World Tuberculosis Day 2024.
Yes!? We can end TB - World Tuberculosis Day 2024.Yes!? We can end TB - World Tuberculosis Day 2024.
Yes!? We can end TB - World Tuberculosis Day 2024.
 
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptx
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptxWORLD TUBERCULOSIS DAY MARCH 24 2021.pptx
WORLD TUBERCULOSIS DAY MARCH 24 2021.pptx
 
ntep.pptx
ntep.pptxntep.pptx
ntep.pptx
 
National tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptxNational tuberculosis elimination programme [Autosaved].pptx
National tuberculosis elimination programme [Autosaved].pptx
 
TB control programs in nepal
TB control programs in nepalTB control programs in nepal
TB control programs in nepal
 
Viral hepatitis Elimination challenges and progress Final.pptx
Viral hepatitis Elimination challenges and progress Final.pptxViral hepatitis Elimination challenges and progress Final.pptx
Viral hepatitis Elimination challenges and progress Final.pptx
 
Revised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in IndiaRevised national tuberculosis control programme (RNTCP) in India
Revised national tuberculosis control programme (RNTCP) in India
 
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptxWORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
WORLD TUBERCULOSIS DAY 2023 AWARENESS.pptx
 
Global health policy - Overview
Global health policy - OverviewGlobal health policy - Overview
Global health policy - Overview
 
Global health policy
Global health policy Global health policy
Global health policy
 
Systematic home screening for active pulmonary tuberculosis in the San commun...
Systematic home screening for active pulmonary tuberculosis in the San commun...Systematic home screening for active pulmonary tuberculosis in the San commun...
Systematic home screening for active pulmonary tuberculosis in the San commun...
 
Systematic home screening for active pulmonary tuberculosis in the san commun...
Systematic home screening for active pulmonary tuberculosis in the san commun...Systematic home screening for active pulmonary tuberculosis in the san commun...
Systematic home screening for active pulmonary tuberculosis in the san commun...
 

Kürzlich hochgeladen

Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyHasnat Tariq
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..AneriPatwari
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 

Kürzlich hochgeladen (20)

Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technology
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 

END TB 2015 strategy

  • 1. PRESENTER : Dr.S.Waseemsha 2yr PG., Dept of PSM GUIDE :Dr.(Col)M.V.Malhotra M.D.,(PSM) Asst.Prof. Dept of PSM
  • 2. OUTLINE OF THE PRESENTATION • Introduction • Burden • Progress • Challenges • Developmental milestones of the strategy • Vision and goal of the strategy • Pillars and principles • Reaching the targets
  • 3. TUBERCULOSIS • TB is a top killer worldwide due to a single infectious agent. • TB places its heaviest burden on the world’s most poor and vulnerable, aggravating existing in equalities. • Due to TB , people face costs or suffer income loss equivalent on average to more than 50% of their income.
  • 4. BURDEN 9 million people fell ill with TB in 2013 1.5 million men, women and children died from TB in 2013 1.1 million people living with HIV developed TB, with 360,000 associated deaths in 2013 480 000 people developed MDR-TB (multidrug- resistant TB) in 2013, with 210,000 associated deaths
  • 5. PROGRESS 37 million lives saved between 2000 and 2013 through effective TB diagnosis and treatment 45% decline in TB mortality rate and 41% decline in TB prevalence rate since 1990 HIV-related TB deaths down by 34% in the last decade Fragile progress in MDR-TB with the number of people diagnosed tripling and a three-fold increase in treatment coverage since 2009
  • 6. CHALLENGES US$ 2 billion funding gap per year for implementation of existing TB interventions. There is an additional gap of US$ 1.39 billion for research. 3 million people with TB are missed by health systems every year and therefore may not get adequate care they need TB/HIV response needs acceleration . Antiretroviral treatment, treatment of latent TB infection and other key interventions still need further scale-up MDR-TB remains a crisis Widening gaps between people diagnosed with MDR-TB and those put on treatment. This could compromise recent gains
  • 7. World Health Assembly 2012 Call from Member States At the 65th World Health Assembly in May 2012, Member States called upon WHO to develop a new post-2015 TB strategy and targets, and present this to Member States at the 67th World Health Assembly in 2014.
  • 8.
  • 9.
  • 10. THE END TB STRATEGY * The United Nations is in the process of defining a post-2015 development agenda. A set of “Sustainable Development Goals” (SDGs) are being developed for 2030; TB is proposed to be part of the agenda and goals.
  • 11. The Strategy: • Provides a unified response to ending TB deaths, disease, and suffering. • Builds on three strategic pillars underpinned by four key principles.
  • 13. PRINCIPLES 1. Government stewardship and accountability, with monitoring and evaluation 2. Strong coalition with civil society organizations and communities 3. Protection and promotion of human rights, ethics and equity 4. Adaptation of the strategy and targets at country level, with global collaboration
  • 14. Pillar 1 INTEGRATED, PATIENT- CENTRED CARE AND PREVENTION A. Early diagnosis of tuberculosis including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups . B. Treatment of all people with tuberculosis including drug-resistant tuberculosis, and patient support . C. Collaborative tuberculosis/HIV activities, and management of co- morbidities D. Preventive treatment of persons at high risk, and vaccination against tuberculosis
  • 15. Pillar 2 A. Political commitment with adequate resources for tuberculosis care and prevention. B. Engagement of communities, civil society organizations, and public and private care providers. C. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control. D. Social protection, poverty alleviation and actions on other determinants of tuberculosis . BOLD POLICIES AND SUPPORTIVE SYSTEMS
  • 16. Pillar 3 INTENSIFIED RESEARCH AND INNOVATION A. Discovery, development and rapid uptake of new tools, interventions and strategies B. Research to optimize implementation and impact, and promote innovations
  • 17. The Global Strategy and targets for Tuberculosis Prevention, Care and Control after 2015, were endorsed by all member states at the 2014 world health assembly.
  • 18. REACHING THE TARGETS Getting to the 2025 targets requires effective use of existing tools to combat TB, complemented by universal health coverage and social protection to: • Push down global TB incidence rates from an annual decline of 2% in 2015 to 10% by 2025. • Reduce the proportion of people with TB who die from the disease from 15% in 2015 to 6.5% by 2025. Moving forward to the 2035 targets requires the ensured availability of new tools from the research pipeline, in particular: • Better diagnostics, including new point-of care tests; • Safer, easier and shorter treatment regimens; • Safer and more effective treatment for latent TB infection; • Effective pre- and post- exposure vaccines.
  • 19. Desired decline in global TB incidence rates to reach the 2035 targets
  • 20. MEASURING PROGRESS • To assess and facilitate progress towards the targets , WHO recommends that countries use the following priority operational indicators. • In 2015,WHO will issue an operational guide with a comprehensive list of recommended indicators and tools for adaptation and implementation of the Strategy.
  • 21. Treatment coverage • Number of people that developed TB, and were notified and treated, out of the total estimated number of incident cases in the same year (%). TB treatment success rate • Number of TB patients who were successfully treated out of all notified TB cases (%).
  • 22. Preventive treatment coverage • Number of people living with HIV and children who are contacts of cases who were started on preventive treatment for latent TB infection, out of all those eligible (%). TB affected households facing catastrophic costs • Number of TB patients and their households that experienced catastrophic costs due to TB, out of all TB patients (%)
  • 23. Uptake of new diagnostics and new drugs • Number of TB patients who were diagnosed using WHO- recommended rapid tests, out of all TB patients (%). • Number of TB patients who were treated with regimens including new TB drugs, out of those eligible for treatment with such drugs (%).